Skip to content

Clinical study on anti-mild hyperlipidemia of Canna edulis RS3 resistant starch

Clinical study on anti-mild hyperlipidemia of Canna edulis RS3 resistant starch

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062871
Enrollment
Unknown
Registered
2022-08-22
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild hyperlipidemia

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. No limitation of ethnic groups; 3. Both sexes; 4. Patients with mild hyperlipidemia: (1) hypertriglyceridemia (1.7 mmol/L <= TG < 2.3 mmol/L), (2) hypercholesterolemia (5.2 mmol/L <= TC < 6.2 mmol/L or 3.4 mmol/L <= LDL-C < 4.1 mmol/L, (3) mixed hyperlipidemia (1.7 mmol/L <= TG < 2.3 mmol/L and 5.2 mmol/L <= TC < 6.2 mmol/L, or 1.7 mmol/L<= TG < 2.3 mmol/L and 3.4 mmol/L<= LDL-C < 4.1 mmol/L,or 1.7 mmol/L <= TG < 2.3 mmol/L and 5.2 mmol/L <= TC < 6.2 mmol/L and 3.4 mmol/L<= LDL-C < 4.1 mmol/L); 5. Have communication and cognitive ability, can adhere to long-term medication; 6. Volunteer to join the experiment.

Exclusion criteria

Exclusion criteria: 1. Those who are receiving lipid-lowering drugs; 2. Hyperlipidemia caused by secondary causes, such as nephrotic syndrome, liver disease, hypothyroidism, renal failure, etc.; 3. Patients with severe diabetes, hypertriglyceridemia, cerebrovascular diseases and other major diseases requiring immediate treatment, and patients with heart disease, immune system diseases, acute onset of chronic diseases, infectious diseases and malignant tumors; 4. Patients with severe primary diseases of liver, kidney and hematopoietic system or mental illness; 5. Pregnant or lactating women; 6. Allergic constitution and allergic to the test drugs; 7. Patients with a history of gallbladder surgery or gastrointestinal polyp surgery that affected the test results; 8. Participating in nutritional intervention studies; 9. Use antibiotics or take probiotics or other prebiotic preparations within 3 months of recruitment.

Design outcomes

Primary

MeasureTime frame
blood lipids;body composition;waistline;gut microbiota;serum lipid metabolites;bile acid;

Secondary

MeasureTime frame
hepatic and renal function;fasting blood-glucose;fasting insulin;serum inflammatory factors;

Countries

China

Contacts

Public ContactXueyong Wang

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine

wxyph.d@163.com+86 15001180832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026